Recent regulatory actions, including two diagnostic clearances and a March 2024 draft guidance, have quietly challenged the assumption that Alzheimer’s trials require cerebrospinal fluid or PET imaging to generate credible biological evidence. Call it the Plasma Pivot: the FDA’s acceptance of blood-based biomarkers as diagnostic anchors is now accelerating faster than most CNS protocol teams have updated their eligibility criteria.
The most recent move came in the form of FDA approval of two new blood tests to detect Alzheimer’s disease in adults with cognitive symptoms, including one intended for adults with cognitive symptoms. On their own, these approvals read like a diagnostic story. Look at them through the lens of clinical trial operations and a different story emerges: the FDA has now formally validated the biological targets that sponsors have been pressured to use as primary outcomes in CNS drug development, and the evidentiary bar just shifted without a press conference announcing it.
The Signal Hidden Inside a Diagnostic Clearance
The first foundational clearance in this sequence came when the FDA cleared the Fujirebio Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio as the first in vitro diagnostic blood test for Alzheimer’s disease, intended for adults with cognitive symptoms. Then, on August 25, 2026, the FDA cleared Roche’s Elecsys Phospho-Tau (217P) Plasma test, developed in collaboration with Eli Lilly, as the first single-biomarker blood test designed to both rule in and rule out amyloid pathology in individuals aged 55 and older with cognitive symptoms. Two tests, two cleared mechanisms, one shared regulatory logic: plasma phosphorylated tau is a scientifically defensible proxy for Alzheimer’s pathology.
That logic does not stay inside the diagnostic box. When the FDA clears a biomarker as sufficient to confirm the presence of disease in clinical practice, it simultaneously signals to drug developers that trials built around that same biomarker carry reduced evidentiary risk. Sponsors who are still designing Phase II protocols around CSF amyloid or amyloid-PET as their sole entry criteria are now operating on a more expensive and arguably less scalable standard than the one the FDA just endorsed for real-world diagnosis.
The FDA’s own March 2024 draft guidance, “Early Alzheimer’s Disease: Developing Drugs for Treatment,” revised from a 2018 draft, explicitly contemplates the use of biomarkers in earlier disease stages before overt symptoms. The two new blood test approvals are not a departure from that framework. They are the diagnostic market catching up to where the guidance was already pointing, and every sponsor still anchored to imaging-heavy entry criteria should treat that as a gap analysis, not a coincidence.
What Screen Failure Data Already Told Us
The operational consequences of staying with legacy entry criteria are measurable. Studies integrating plasma pTau217 as a pre-screening tool in Alzheimer’s trials, including work referenced in the AHEAD Study design, reduced screen failure rates from 75% to below 25%. That is not a marginal efficiency gain. A 50-percentage-point reduction in screen failure translates directly into site burden, recruitment timelines, and per-patient cost, particularly for early-stage disease where amyloid positivity rates in the general symptomatic population are nowhere near 100%.
Here is the counterintuitive framing most CNS teams miss: the conventional wisdom holds that adding a blood-based pre-screen complicates the eligibility cascade and creates an additional protocol step that sites must manage. The data inverts that assumption. Fewer failed screens means fewer wasted site visits, fewer informed consent withdrawals after a lumbar puncture confirms ineligibility, and fewer investigators who stop referring patients because the burden-to-enrollment ratio is too punishing. The blood test simplifies the funnel even though it adds a step to the paper protocol.
A real-world study presented at the Alzheimer’s Association International Conference 2026 confirmed that blood-based biomarker testing significantly improved diagnostic accuracy in both primary and specialty care settings. That finding matters for trial design because it means the testing infrastructure is migrating toward settings where sponsors can reach earlier-stage patients at scale, primary care offices, not just academic memory clinics. The recruitment geography of an Alzheimer’s trial built around blood-based entry criteria looks fundamentally different from one built around PET availability.
The Endpoint Question Sponsors Are Avoiding
Diagnostic clearance and trial endpoint acceptance are legally distinct, but regulatorily intertwined. The FDA’s clearance of the first single-biomarker blood test for Alzheimer’s, the Roche-Lilly Elecsys pTau217 test, carries a specific claim: the assay can rule in and rule out amyloid pathology. A blood test with that cleared label is a short evidentiary step away from serving as a primary or co-primary endpoint in a Phase III trial measuring amyloid clearance or tau reduction as a treatment effect.
Sponsors building protocols today should be asking whether their primary endpoints can be anchored to plasma biomarkers that now carry FDA-cleared diagnostic validity, rather than endpoints that require a lumbar puncture or 90-minute PET scan every six months. The answer will differ by mechanism of action and by what the agency has already accepted in prior SPAs. But the question is no longer hypothetical.
The real-world evidence dimension compounds this further. With FDA-cleared blood tests now available in primary care settings, large health systems will begin generating plasma biomarker data at scale, data that was functionally impossible to collect under the CSF and PET paradigm. That creates a real-world evidence substrate for Alzheimer’s that did not exist two years ago. Sponsors who are not already in conversations with integrated health networks about prospective biomarker registries are behind the infrastructure curve, not just the regulatory one.
CROs and technology vendors face a version of this problem that moves faster. The eCOA and EDC vendors who have built their Alzheimer’s trial modules around imaging-based endpoints, scheduling PET windows, managing CSF collection visit logistics, flagging imaging read discordances, will need to rebuild those workflows around blood draw cadences and plasma assay turnaround. The sites running these trials need training on a different sample handling protocol. The RTSM systems randomizing patients based on amyloid-positive PET status need a new eligibility branch. None of that is trivial, and none of it waits for the next indication.
In 12 to 18 months, the first sponsor to submit a Phase III NDA for an Alzheimer’s therapeutic using plasma pTau217 as a co-primary endpoint will either set a precedent that accelerates the entire field or receive a complete response letter that clarifies exactly where the FDA draws the line between diagnostic validity and efficacy evidence. Either outcome is more valuable than the current strategy of watching from the sidelines while designing protocols around a biological measurement infrastructure the FDA just signaled it no longer requires.
References
- JAMA, “FDA Approves 2 New Alzheimer Disease Blood Tests”
- FDA, “FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease” (Fujirebio Lumipulse G pTau217/Beta-Amyloid 1-42)
- Pharmacy Times, “FDA Clears Elecsys Phospho-Tau Blood Test for Alzheimer Disease” (Roche/Lilly, August 25, 2026)
- Worldwide Clinical Trials, “Role of Biomarkers in AD Clinical Trials” (FDA March 2024 Draft Guidance discussion)
- PMC, “Blood-Based Biomarkers and Screen Failure Reduction in Alzheimer’s Trials” (AHEAD Study, pTau217 pre-screening data)
- Alzheimer’s Association International Conference 2026, “Alzheimer’s Blood Test Accurate for Diagnosis in Primary and Specialty Care”
- AJMC, “FDA Clears First Single Biomarker Blood Test for Alzheimer’s” (Roche Elecsys pTau217)
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
